Don’t prescribe neither chemotherapy nor radiotherapy in the treatment of ductal carcinoma in situ of the breast.
The widespread screening for early detection of breast cancer has led to the frequent identification of early forms of cancer, especially carcinoma in situ: lobular carcinoma in situ and, more frequently, ductal carcinoma in situ (DCIS). Since these types of cancer...
Don’t perform laboratory tests (including biochemical profile), imaging (chest x-rays, liver and pelvic ultrasound, PET, CT and radionuclide bone scans) or serum cancer markers for asymptomatic patients after surgery for breast cancer, in the absence of clinical signs.
Physical examination (medical examination) should be performed every 3-6 months for the first three years, every 6-12 months for the fourth and fifth year, and annually thereafter. In women undergoing breast-conserving surgery should be performed a bilateral...
Don’t routinely use cancer-directed therapy for solid tumor patients with low performance status (3 or 4) or progressive after 2-3 therapeutic lines, but prioritize palliative care.
The anticancer treatments in general are likely to be ineffective in patients with solid tumors with the following characteristics: low performance status (3-4), no response to previous evidence-based therapies, not eligibility for a clinical trial, the absence of...
Don’t routinely prescribe serum cancer markers during the diagnostic or staging procedures in cancer care.
The serum tumor markers are often required in an appropriate way as they need a simple blood sample. Given the high cost of each prescription tests and the high number of required tests it represents a considerable employment of resources; in addition it represents a...The campaign DOING MORE DOES NOT MEAN DOING BETTER – CHOOSING WISELY ITALY is promoted by Italy’s Slow Medicine
Recent Comments